You have 0 items in your cart
Metabolic research has produced an interesting scientific puzzle.
Some investigational compounds are designed to activate the GIP receptor alongside GLP-1.
Another emerging compound is investigating almost the opposite strategy.
MariTide activates the GLP-1 receptor while blocking the GIP receptor.
That apparent contradiction makes MariTide — formally known as maridebart cafraglutide — one of the more unusual compounds currently progressing through metabolic research.
What Is MariTide?
MariTide, previously known as AMG 133, is an investigational compound being developed by Amgen.
Its full generic name is maridebart cafraglutide.
Rather than being a conventional peptide agonist, MariTide is a long-acting antibody-peptide conjugate.
Its molecular design combines two different actions:
GLP-1 receptor agonism
and
GIP receptor antagonism
In simpler terms, one part of its mechanism activates GLP-1 signalling while another is designed to inhibit signalling through the GIP receptor.
That gives MariTide a notably different pharmacological profile from many other metabolic compounds under investigation.
What Does GIP Antagonism Mean?
An agonist activates a receptor.
An antagonist blocks or reduces activation of a receptor.
Therefore:
GIP agonism = activation of the GIP receptor
GIP antagonism = inhibition of GIP receptor signalling
This distinction is particularly interesting because GIP receptor activation is itself being investigated in other areas of metabolic pharmacology.
Scientists are therefore studying apparently opposing approaches to the same receptor.
Why Would Researchers Block GIP?
Amgen’s development programme was influenced partly by human genetic research.
Genetic studies suggested that reduced GIP receptor signalling could potentially be relevant to metabolic regulation.
Researchers subsequently investigated whether combining GIP receptor antagonism with GLP-1 receptor agonism could create a useful pharmacological profile.
This highlights an important feature of modern drug development.
Researchers aren’t limited to copying the behaviour of naturally occurring hormones.
They can use genetic and biological evidence to investigate whether increasing or decreasing activity within particular signalling systems produces useful effects.
An Interesting Scientific Paradox
MariTide creates one of the most interesting questions in contemporary metabolic research.
How can researchers investigate both GIP activation and GIP inhibition?
The answer lies in the complexity of receptor biology.
Metabolic pathways don’t operate as simple switches where activation is always beneficial and inhibition is always harmful, or vice versa.
Effects can depend on factors including:
- the tissues involved
- duration of receptor activity
- interactions with other hormones
- receptor sensitivity
- pharmacological exposure
- the wider metabolic environment
Consequently, different molecular strategies involving the same receptor can potentially produce very different biological effects.
MariTide’s Antibody-Peptide Design
Another distinctive feature is its structure.
MariTide is an antibody-peptide conjugate.
This combines peptide pharmacology with properties associated with antibody-based medicines.
One objective of this molecular engineering is to create much longer pharmacological activity than would normally be expected from many conventional peptides.
That leads to another important feature of MariTide research: dosing frequency.
Why Is MariTide Being Studied for Less Frequent Administration?
Many metabolic therapies have been developed around daily or weekly administration.
MariTide’s long-acting molecular design allows researchers to investigate substantially longer intervals.
Amgen’s development programme includes monthly administration, with research also examining intervals extending beyond one month.
This creates an entirely different research question.
Instead of simply asking whether a compound produces a biological response, researchers can examine whether that response can be maintained with considerably less frequent administration.
What Did Phase 2 Research Find?
A randomised Phase 2 study published in the New England Journal of Medicine investigated MariTide in adults with obesity, including a separate cohort with type 2 diabetes.
The study involved 592 participants.
After 52 weeks, statistically significant changes in body weight were observed across the investigated MariTide groups compared with placebo.
Researchers also examined metabolic measures and safety outcomes.
Gastrointestinal adverse events were commonly reported, particularly during treatment initiation, while different escalation strategies were investigated to improve tolerability.
These findings supported progression into a larger Phase 3 programme.
What Happened During Longer-Term Research?
Research didn’t stop after the initial 52-week period.
Amgen subsequently investigated whether changes achieved during the first year could be maintained during a second year using lower or less frequent administration.
The company reported in 2026 that the large majority of participants meeting the extension criteria maintained their previous weight reduction while receiving lower monthly or quarterly administration.
These findings remain part of an ongoing investigational programme rather than evidence of regulatory approval.
What Is the MARITIME Programme?
MariTide has now progressed into Phase 3 development through Amgen’s MARITIME programme.
Research is examining several populations and conditions.
These include people with obesity or overweight both with and without type 2 diabetes.
Additional studies are investigating cardiovascular outcomes, heart failure and obstructive sleep apnoea.
One particularly interesting study is examining people transitioning from weekly metabolic therapies to MariTide using substantially longer administration intervals.
Long-term extension studies are also investigating maintenance using monthly, eight-week and quarterly schedules.
Why Long-Acting Research Matters
Long duration isn’t simply a convenience issue.
It raises important scientific questions involving pharmacokinetics — what happens to a compound after it enters the body.
Researchers need to understand:
- how long concentrations remain biologically active
- how exposure changes between administrations
- whether biological effects persist
- how adverse effects relate to exposure
- whether extended intervals alter treatment responses
Designing molecules with significantly longer activity therefore represents its own branch of pharmaceutical research.
MariTide Shows That Metabolic Research Isn’t Following One Formula
The development of MariTide illustrates something important about the current research landscape.
Scientists aren’t converging on one universal metabolic mechanism.
They’re investigating very different strategies.
Some research activates multiple receptors.
Some selectively targets one pathway.
Some combines different hormonal systems.
MariTide investigates activation of one receptor alongside inhibition of another.
And its antibody-peptide architecture adds another layer by exploring substantially longer duration of activity.
Why MariTide Is Worth Following
MariTide is interesting not simply because another metabolic compound has entered Phase 3 research.
Its mechanism challenges an overly simple understanding of modern metabolic pharmacology.
More receptor activation isn’t necessarily the only research strategy.
Researchers are increasingly investigating the balance, inhibition, duration and interaction of signalling pathways.
MariTide demonstrates this particularly clearly.
Its combination of GLP-1 receptor agonism, GIP receptor antagonism and long-acting antibody-peptide engineering makes it one of the more distinctive programmes within the current generation of metabolic research.
Future Phase 3 results should provide considerably more evidence about this unusual pharmacological approach.
Research Notice: MariTide (maridebart cafraglutide) is an investigational compound. This article is provided for scientific and educational information only and does not constitute medical advice, treatment guidance or dosing information.